Back

Characteristics of patients initiating dapagliflozin for heart failure with reduced ejection fraction in Italian clinical practice: a 6-month interim analysis of EVOLUTION-HF Italy

11 May 2024 (08:00 - 20:00)
Organised by: Logo
Congress Presentation Part of: Chronic heart failure - treatment 7 Pharmacotherapy HFA Premium Access Heart Failure 2024 Heart Failure Association (HFA)

About the speaker

Photo
Associate Professor Pietro Ameri

University of Genoa, Genova (Italy)

7 More presentations in this session

Presentation thumbnail
A prospective interventional randomized study to assess efficacy of angiotensin receptor neprilysin inhibitor in right ventricular systolic dysfunction with normal left ventricular systolic function.
Doctor R. Mathur (Jodhpur, IN)
Abstract Slides Video
Presentation thumbnail
Optimization of pharmacological treatment of heart failure in patients followed in specialized HF units in Spain.
Doctor R. Gonzalez-Manzanares (Cordoba, ES)
Abstract Slides Video
Presentation thumbnail
Tafamidis for the treatment of transthyretin cardiac amyloidosis (ATTR-CM) - Real-world data from a tertiary center.
Doctor R. Carvalho (Lisbon, PT)
Abstract Slides Video
Presentation thumbnail
Asymptomatic versus symptomatic hypotension in HFrEF: Findings with sacubitril/valsartan in PARADIGM-HF
Doctor S. Matsumoto (Tokyo, JP)
Abstract Slides Video
Presentation thumbnail
Diuresis efficacy in ambulatory congested heart failure patients: Intra -patient comparison of three diuretic regimens (DEA-HF)
Doctor A. Abbo (Haifa, IL)
Abstract Slides Video

Access the full session

Session thumbnail
Chronic heart failure - treatment 7

The Event

Event poster

Heart Failure 2024

11 May - 14 May 2024
You may be interested in
thumbnail
Congress Presentation
Effects of Dapagliflozin on myocardial performance in non-diabetic patients with Heart failure with reduced and mid-range ejection fraction (DAPA ECHO trial)
thumbnail
Congress Presentation
Dapaglifozin in advanced heart failure patients : effects on congestion, NTproBNP and cardiorenal outcome
thumbnail
Congress Presentation
Dapagliflozin effect on cardiopulmonary function, reverse cardiac remodelling and biomarkers in a cohort of HFrEF patients

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources